GCG and colitis: To directly test the role of GLP-1 in gut inflammation, we blocked GLP-1 receptor during high-dose DSS colitis (6% DSS), a condition in which we observed a significant rise in plasma GLP-1 levels, using the GLP-1 receptor antagonist Exendin-9-39 (Fig. 1H).